More on ARQT

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (+216.7% Growth)
- Ratings (8.2 Score)
- FDA

Upcoming Events

- Earnings (10/29/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Arcutis Biotherapeutics (NQ:ARQT)
Delayed: 28.82 -0.28 (0.96%)
Prev. Close $29.10  
Open$29.18 
52 Wk High$ 
52 Wk Low$ 
Day High$29.37 
Day Low$28.15 
P/E N/A  
EPS$ 
Volume1,801,748 

Friends, Peers and Foes (?): INCY, PVLA, GNLX, MBX, NAMS (more...)

Oct 15, 2026 03:57 PM Form 144 Arcutis Biotherapeutics, Filed by: Welgus Howard G.
Oct 15, 2026 06:34 AM Cantor Fitzgerald Resumes Arcutis Biotherapeutics Inc. (ARQT) at Overweight
Oct 9, 2026 08:01 AM Arcutis presents Zoryve and corticosteroid data at dermatology meetings
Oct 9, 2026 08:00 AM Arcutis Presents ZORYVE® (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV and Fall Clinical
Oct 8, 2026 04:23 AM Jefferies Reiterates Buy Rating on Arcutis Biotherapeutics Inc. (ARQT) ahead of earnings
Oct 6, 2026 08:19 AM Arcutis’ ZORYVE® (roflumilast) Wins 2026 Marie Claire Beauty Award
Oct 5, 2026 11:59 AM Form SCHEDULE 13G/A Arcutis Biotherapeutics, Filed by: BlackRock, Inc.
Oct 2, 2026 04:00 PM Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 29, 2026 09:15 AM Simone Biles Partners with Arcutis to Launch the Skin to Believe In Campaign, Raising Awareness of Seborrheic Dermatitis and Eczema, and Inspiring People to Explore Treatment Options
Sep 18, 2026 04:17 PM Form 4 Arcutis Biotherapeutics, For: Sep 16 Filed by: Matsuda Masaru
View All Articles

Entities mentioned with ARQT

View All Entities